OTCMKTS:BNVIQ - Bionovo Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.0003 0.00 (0.00 %)
(As of 11/13/2018 04:00 PM ET)
Previous Close$0.0003
Today's Range$0.0003 - $0.0003
52-Week Range$0.0003 - $0.0027
VolumeN/A
Average Volume96,632 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Bionovo, Inc. is a drug discovery and development company, which focuses on women's health and development of drugs for the treatment of cancer. The Company's drug candidates include Menerba, Seala, Bezielle, BN107 and BN108. Its Menerba is a selective estrogen receptor beta agonist, which reduces the frequency and severity of menopausal hot flashes. The Company has completed a randomized, double-blind, placebo-controlled Phase II clinical trial of Menerba. Bezielle is an orally delivered anti-cancer agent. The Company is engaged in an open label, multi-center Phase I/II trial of Bezielle for the treatment of advanced metastatic breast cancer. The Company's Seala is a selective estrogen receptor beta agonist, which acts as an intra-vaginal suppository. The Company's anti-cancer agents include BN107 and BN108, which are used for the treatment of advanced breast cancer. BN107 and BN108 are in pre-clinical development stage.

Receive BNVIQ News and Ratings via Email

Sign-up to receive the latest news and ratings for BNVIQ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:BNVIQ
Previous SymbolNASDAQ:BNVI
CUSIPN/A
Phone+1-510-6012000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00
OptionableN/A

Bionovo (OTCMKTS:BNVIQ) Frequently Asked Questions

What is Bionovo's stock symbol?

Bionovo trades on the OTCMKTS under the ticker symbol "BNVIQ."

Has Bionovo been receiving favorable news coverage?

Press coverage about BNVIQ stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bionovo earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave media headlines about the healthcare company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the near future.

How do I buy shares of Bionovo?

Shares of BNVIQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bionovo's stock price today?

One share of BNVIQ stock can currently be purchased for approximately $0.0003.

What is Bionovo's official website?

The official website for Bionovo is http://bionovo.com/.

How can I contact Bionovo?

Bionovo's mailing address is 5858 Horton St Ste 400, EMERYVILLE, CA 94608-2046, United States. The healthcare company can be reached via phone at +1-510-6012000.


MarketBeat Community Rating for Bionovo (OTCMKTS BNVIQ)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  24 (Vote Underperform)
Total Votes:  60
MarketBeat's community ratings are surveys of what our community members think about Bionovo and other stocks. Vote "Outperform" if you believe BNVIQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BNVIQ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel